Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

893 recalls · Class II, newest first

Class II · Moderate risk

Early Baby TPN

Labeling: Not Elsewhere Classified: Products may contain synthetic latex and/or natural latex.

Terminated Labeling / mix-up Advanced Pharma Inc. D-0806-2017
Class II · Moderate risk

Early TPN (Neonatal)

Labeling: Not Elsewhere Classified: Products may contain synthetic latex and/or natural latex.

Terminated Labeling / mix-up Advanced Pharma Inc. D-0805-2017
Class II · Moderate risk

TPN Neonatal all strengths

Labeling: Not Elsewhere Classified: Products may contain synthetic latex and/or natural latex.

Terminated Labeling / mix-up Advanced Pharma Inc. D-0803-2017
Class II · Moderate risk

Ofirmev (Acetaminophen)

Labeling: Not Elsewhere Classified: Products may contain synthetic latex and/or natural latex.

Terminated Labeling / mix-up Advanced Pharma Inc. D-0800-2017
Class II · Moderate risk

Nalbuphine all strengths

Labeling: Not Elsewhere Classified: Products may contain synthetic latex and/or natural latex.

Terminated Labeling / mix-up Advanced Pharma Inc. D-0797-2017
Class II · Moderate risk

Lidocaine all strengths

Labeling: Not Elsewhere Classified: Products may contain synthetic latex and/or natural latex.

Terminated Labeling / mix-up Advanced Pharma Inc. D-0796-2017
Class II · Moderate risk

Dorama-Neo

Lack of Assurance of Sterility: Firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.

Terminated Sterility / contamination Sato Pharmaceutical Inc. NDC 49873-020-01 D-0856-2017
Class II · Moderate risk

Sato Clear

Lack of Assurance of Sterility: Firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.

Terminated Sterility / contamination Sato Pharmaceutical Inc. NDC 49873-044-01 D-0855-2017
Class II · Moderate risk

Optic Splash

Lack of Assurance of Sterility: Firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.

Terminated Sterility / contamination Sato Pharmaceutical Inc. NDC 49873-501-01 D-0854-2017
Class II · Moderate risk

Famciclovir tablets

Failed impurities/ degradation specifications: Product was above specification for unknown impurities.

Terminated Impurity / degradation AVKARE Inc. NDC 50268-307-13 D-0610-2017

Recalls by year